Our Narrative

Aug 2016
Mar 2017
Nov-Dec 2017
Mar 2018
April 2018
September 2019
February 2020
June 2020
April 2021
Dec 2021 to May 2022


Founded in Bangalore, India. $6Mio seed funding by Accel, Aarin, IDG, KITVEN


Development of technology platforms. Glyco-Engineering. Naïve & Synthetic Display Libraries. Development of trastuzumab biosimilar and Exendin-4.


Zumutor incorporated in USA with office in MA. Series A $6 Mio raised from existing investors. Global patents filed.

Aug 2016

Research collaboration signed with global major, Catalent, for ADCC enhancement

Mar 2017

Ideation and selection. 21 immunotherapy targets chosen.

Nov-Dec 2017

In vivo efficacy study with lead molecule initiated. Out licensed Trastuzumab biosimilar.

Mar 2018

Mouse study reveals signficant reduction in tumour growth compared to “Control IgG”.

April 2018

Raised $ 4 Mio from Accel for preclinical studies

September 2019

Raised $ 4 million as Series A 2 funds

February 2020

– Zumutor partners with Catalent for Ab production

– HuNog Mouse efficacy data completed

– Partnership with Mt. Sinai for tissue data analysis

June 2020

Pharm Tox studies nearing completion

April 2021

  • Completed Pharm Tox studies with excellent PK, PD data
  • Completed Efficacy Studies
  • Completed DS manufacturing at 250L Scale
  • Completed MOA studies
  • On-going – Ex-Vivo Patient Translational data studies

Dec 2021 to May 2022

  • Raised 6.2Mil$ in capital (from Accel Partners, Siana Capital, Barath Innovation Fund)
  • Successfully Completed GLP Tox studies
  • Completed DS manufacturing at 250L Scale
  • Completed PIND(Pre IND submission) for ZM008
  • Ex-Vivo studies ongoing : Promising date in Monotherapy and combination


  • Zumutor has developed a fully human proprietary mAb technology platform (INABLR™) that facilitated rapid identification of selective and potent mAbs with potential to enhance ADCC activity
  • ZM008 is a fully human IgG1 which blocks the interaction between LLT1(on tumor cell) and CD161(on NK), there by activating NK cell and the downstream tumor killing MOA has been established
  • Our partnerships with leading clinical centers like Mt Sinai-NYC and other hospital groups for patient centric data approaches validates our robust approach for ensuing Phase 1 studies
  • Zumutor looks to drive value driven opportunities of licensing the asset (currently preclinical) in multiple geographies
  • Zumutor looks to partner and collaborate for other immuno-onco targets that could drive novel Ab hits through the INABLR™ platform
  • We are actively seeking opportunities to partner development of bispecifics/ CART/ CAR-NK molecules using our proprietary antibody discovery platforms to fast-track development
  • We offer flexible- full service bespoke services for analytical and process development

For information on partnering and collaborations, please write to kavithaiyer.rodrigues@zumutor.com

Zumutor and Syngene Press Release

Syngene International, a leading global Contract Research Services Company, has entered into a non-exclusive partnering agreement with Zumutor Biologics, an emerging immunooncology Company, to access Zumutor’s proprietary naïve human phage/yeast display library. This collaboration further enhances Syngene’s market-leading capabilities in Discovery Biology, providing its scientists with additional tools to help solve complex biology problems in biotherapeutic drug discovery

Prof. Vijay Kuchroo Laboratory and Zumutor Ink Agreement

On 12 November, 2019 Zumutor Biologics and Prof. Vijay Kuchroo Laboratory (Evergrande Center for Immunologic Diseases at Harvard Medical School and Brigham and Women’s Hospital Ann Romney Center for Neurologic Diseases) have inked an agreement to discover unique human monoclonal antibodies against a novel cytokine identified by Kuchroo Laboratory. Zumutor will use its proprietary antibody discovery platform INABLR® to identify novel antibody clones against the cytokine

Catalent and Zumutor Biologics Collaborate to Manufacture First-in-Class mAb to Treat Solid Tumors

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it has signed an agreement with Zumutor Biologics, Inc., to manufacture Zumutor’s lead candidate, ZM008, for the treatment of solid tumors

Our Team

We have committed our resources to develop treatment of cancer through next generation immunotherapies and have assembled a highly experienced team to execute our vision

Kavitha Iyer Rodrigues
Kavitha Iyer RodriguesChief Executive Officer
Kavitha is well known throughout the biotech community for her entrepreneurial acumen and leadership. She is passionate about setting new global benchmarks through Zumutor
Dr. Maloy Ghosh
Dr. Maloy GhoshChief Scientific Officer
Maloy heads our R &D . He is an expert in the areas of cancer biology, stem cell and biomarker development.
Anirban Bhattacharya
Anirban BhattacharyaChief Financial Officer
Experienced in licensing, mergers and acquisitions in the biopharmaceutical industry, Anirban is a consummate finance professional


Dr. Pradip Mazumdar
Dr. Pradip MazumdarLeader in Cancer Drug Discovery; Visiting faculty of Dana-Farber Cancer Institute
Boston, MA
Andy Rakestraw
Andy RakestrawFounder Celexion LLC & Management Team at Torque
Cambridge, MA
Prof. Raghavan V
Prof. Raghavan VChairman, MBU Indian Institute of Science
Bengaluru, India
Ana Anderson
Ana AndersonAss. Prof @ HMS, Member of Broad Institute of MIT, Harvard
Boston, MA
Karthik Viswanathan
Karthik ViswanathanDirector, Research at Visterra, Inc
Cambridge, MA
Dr. Anurag Rathore
Dr. Anurag RathoreProfessor, Chemical Engineering IIT
New Delhi, India
Dr. Stephen Hodi
Dr. Stephen HodiProf of Medical Oncology, Dana-Farber; Prof of Medicine, Harvard Med School
Boston, MA
Narendra Chirmule
Narendra ChirmuleCEO, Director, Co-Founder Symphonytech Biologics
Bengaluru, India


Prof. Emeritus Charles Cooney
Prof. Emeritus Charles CooneyRobert T. Haslam Professor of Chemical Engineering Education
MIT, Cambridge, MA
Patrick Vink
Patrick VinkAdvisor, Global Biotechnology Industry Chairman, Targovax, NM Pharma
Zurich Area, Switzerland
Mark Wolters
Mark WoltersEx-Vice President, Bayer Life Science; Advisory Board, Celmatix & Fraunhofer Institute for Cell Therapy and Immunology
Berlin, Germany

Our Clinical Partners

Our VC Partners

We have raised US$ 26 million in capital from Accel, IDG ventures, Aarin Capital, KITVEN, BIF and Siana Capital

Discover The Future

We attract, retain and nurture scientific talent that shares our dream of pushing the boundaries of therapeutic research. We believe in innovation and a science-based approach.

Contact Us